Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Accounting for tumor heterogeneity in the development of predictive biomarkers.

Siu LL.

Clin Adv Hematol Oncol. 2013 May;11(5):312-3. No abstract available.

PMID:
23880715
2.

Next generation sequencing applications in cancer research.

Zhang W, Nykter M, Chen K.

Cancer Lett. 2013 Nov 1;340(2):149-50. doi: 10.1016/j.canlet.2013.05.026. Epub 2013 Jun 11. No abstract available.

PMID:
23764479
3.

Genetic heterogeneity in breast cancer: the road to personalized medicine?

Baird RD, Caldas C.

BMC Med. 2013 Jun 18;11:151. doi: 10.1186/1741-7015-11-151. Review.

4.

Personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19. Review.

PMID:
22999010
5.

Transcript profiling towards personalised medicine in rheumatoid arthritis.

Verweij CL.

Neth J Med. 2009 Dec;67(11):364-71. Review.

6.

[Great potential of miRNAs as predictive and prognostic markers for cancer].

Cho WC.

Zhongguo Fei Ai Za Zhi. 2013 Jan;16(1):C1-4. doi: 10.3779/j.issn.1009-3419.2013.01.12. Review. Chinese. No abstract available.

7.

Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges.

Horswell S, Matthews N, Swanton C.

Cancer Lett. 2013 Nov 1;340(2):220-6. doi: 10.1016/j.canlet.2012.10.031. Epub 2012 Nov 8. Review.

PMID:
23142290
8.

Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.

Lee AJ, Swanton C.

Biochem Pharmacol. 2012 Apr 15;83(8):1013-20. doi: 10.1016/j.bcp.2011.12.008. Epub 2011 Dec 16. Review.

PMID:
22192819
9.

Biomarkers and oncology: the path forward to a learning health system.

Yu PP, Hoffman MA, Hayes DF.

Arch Pathol Lab Med. 2015 Apr;139(4):451-6. doi: 10.5858/arpa.2014-0080-ED. Epub 2014 Aug 25. No abstract available.

PMID:
25152310
10.

Is there a role of Eastern Europe in cancer biomarkers for personalized cancer medicine?

Berindan-Neagoe I, Paradiso A.

Cancer Biomark. 2014;14(2-3):85-6. doi: 10.3233/CBM-130342. No abstract available.

PMID:
24878808
11.

[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].

Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2012;106(1):11-22. doi: 10.1016/j.zefq.2011.12.001. Epub 2012 Jan 10. Review. German.

PMID:
22325103
12.

[Translational research - towards personalized medicine].

Tokui T.

Nihon Yakurigaku Zasshi. 2013 Mar;141(3):122-5. Review. Japanese. No abstract available.

PMID:
23470475
13.

[New directions in biomarker research, drug development and personalized medicine].

NĂ©meth G, Jelinek I.

Magy Onkol. 2013 Mar;57(1):5-10. doi: MagyOnkol.2013.57.1.5. Epub 2013 Feb 10. Review. Hungarian.

14.

From genomic landscapes to personalized cancer management-is there a roadmap?

Swanton C, Caldas C.

Ann N Y Acad Sci. 2010 Oct;1210:34-44. doi: 10.1111/j.1749-6632.2010.05776.x.

PMID:
20973797
15.

Next-generation sequencing in the clinic: promises and challenges.

Xuan J, Yu Y, Qing T, Guo L, Shi L.

Cancer Lett. 2013 Nov 1;340(2):284-95. doi: 10.1016/j.canlet.2012.11.025. Epub 2012 Nov 19. Review.

PMID:
23174106
16.

Personalized medicine in oncology: tailoring the right drug to the right patient.

Jiang Y, Wang M.

Biomark Med. 2010 Aug;4(4):523-33. doi: 10.2217/bmm.10.66. Review.

PMID:
20701441
17.

The challenge of intratumour heterogeneity in precision medicine.

Seoane J, De Mattos-Arruda L.

J Intern Med. 2014 Jul;276(1):41-51. doi: 10.1111/joim.12240. Review.

18.

Progress towards personalized medicine.

Bates S.

Drug Discov Today. 2010 Feb;15(3-4):115-20. doi: 10.1016/j.drudis.2009.11.001. Epub 2009 Nov 13. Review.

PMID:
19914397
19.

Personalized cancer genomics: the road map to clinical implementation.

Yousef GM.

Clin Chem. 2012 Apr;58(4):661-3. doi: 10.1373/clinchem.2011.181073. Epub 2012 Feb 9. No abstract available.

20.

Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.

Gandara DR, Li T, Lara PN Jr, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW.

Clin Lung Cancer. 2012 Sep;13(5):321-5. doi: 10.1016/j.cllc.2012.05.004. Epub 2012 Jun 6. No abstract available.

Supplemental Content

Support Center